How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,067 results for

Thromboembolic Disease in Pregnancy


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Thrombosis Outcomes in Pediatric Venous Thromboembolism

biomarkers in children that develop poor VTE outcomes (such as recurrence, postthrombotic syndrome and post PE impairment ) after an initial VTE with those that do not develop such outcomes. Condition or disease Venous Thromboembolism Detailed Description: All newly diagnosed patients with a first radiologically confirmed thrombotic event (any site) diagnosed at Children's Medical Center, Dallas will be followed prospectively with global coagulation assessment over a 24-month period, and monitored (...) malignancy Pregnancy or immediate post-partum period (12 weeks after delivery) Sickle cell disease Known bleeding disorder Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT03068923 Contacts Layout table for location contacts Contact: Kendra Malone, MPH

2017 Clinical Trials

162. Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

: Duke University Collaborator: Patient-Centered Outcomes Research Institute Information provided by (Responsible Party): Duke University Study Details Study Description Go to Brief Summary: Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Warfarin Drug: Apixaban 2.5 MG Drug: Rivaroxaban 10 MG Phase 4 Detailed Description: Determine if apixaban is superior (...) twice daily, would not be appropriate therapy) A clinical indication for a specific anticoagulant regimen (e.g., warfarin with a target INR of 2-3 is recommended for patients with 'triple-positive' antiphospholipid syndrome). Life expectancy < 3 months Currently pregnant or breast feeding Unable / unwilling to pay for one (or more) of the treatment options Active Cancer defined as: Diagnosed with cancer within the past 6 months; or Recurrent, regionally advanced or metastatic disease; Currently

2017 Clinical Trials

163. Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure

thromboembolism in first-degree relatives of women who did not have venous thromboembolism during a similar hormonal exposure. The primary objective is to determine the association between the presence or the absence of VTE in young women during hormonal exposure and the presence or the absence of a previous episode of VTE in their first-degree relatives. Secondary objective is to determine the impact of associated inherited thrombophilia on the risk of VTE in first-degree relatives. Condition or disease (...) See Sponsor: University Hospital, Brest Information provided by (Responsible Party): University Hospital, Brest Study Details Study Description Go to Brief Summary: Young women have an increased risk of venous thromboembolism (VTE) during hormonale exposure (estrogen-containing pill or pregnancy). In order to detect women at higher risk of VTE during hormonal exposure, thrombophilia testing is often performed in order to adapt contraception methods and/or to increases thromboprophylaxy during

2017 Clinical Trials

164. Incidence and risk factors of venous thromboembolism during postpartum-period: a population-based cohort-study. Full Text available with Trip Pro

, primiparity, cesarean section, cardiac/renal diseases, and varicose veins were associated with an increased risk for postpartum venous thromboembolic events. The risk remained elevated for 180 days in women with thrombophilia, cesarean section, multiple pregnancy, varicose veins, and cardiac disease.The risk of venous thromboembolic events remained elevated compared with that of the nonpregnant women after the usually defined postpartum period (6 weeks). The results might assist in selecting women in need (...) , declining to two-fold immediately after that. Almost half of the venous thromboembolic events occurred between 43 and 180 days postpartum. The incidence of venous thromboembolic events was four-fold compared with that of nonpregnant women. Three venous thromboembolic events-related deaths occurred. Older age, higher body mass index, thrombophilia, multiple pregnancy, gestational diabetes, anemia, chorioamnionitis, threatening premature birth, in vitro fertilization with ovarian hyperstimulation

2017 Acta Obstetricia et Gynecologica Scandinavica

165. Hepatic infarction in a pregnant woman with antiphospholipid syndrome and triple antibody positivity: A case report focusing on catastrophic antiphospholipid syndrome Full Text available with Trip Pro

Hepatic infarction in a pregnant woman with antiphospholipid syndrome and triple antibody positivity: A case report focusing on catastrophic antiphospholipid syndrome Pregnant women with antiphospholipid syndrome (APS) carry a high risk of arterial or venous thrombosis. Such thrombotic conditions occur more frequently in patients with triple positivity to antiphospholipid antibodies or with high antibody titers. Hepatic infarction is a rare complication in pregnant women with APS (...) , and it sometimes mimics HELLP syndrome. This report describes a preeclamptic pregnant woman with APS who had high titers of three antiphospholipid antibodies. She experienced severe epigastric pain with elevated liver enzymes; in addition, she had tachycardia and tachypnea. The clinical findings suggested hepatic infarction and pulmonary thromboembolism, a partial manifestation of catastrophic APS. Therefore, she underwent emergent cesarean section at 25+2 weeks of gestation. After the delivery, her laboratory

2016 Obstetrics & gynecology science

166. Weight management before, during and after pregnancy

with, or who are receiving treatment for, an existing condition such as type 1 or type 2 diabetes food safety advice. The guidance is for NHS and other commissioners, managers and professionals who have a direct or indirect role in, and responsibility for, women who are pregnant or who are planning a pregnancy and mothers who have had a baby in the last 2 years. This includes those working in local authorities, education and the wider public, private, voluntary and community sectors. It is particularly (...) folic acid supplements. This includes professionals working in pre-conception clinics, fertility clinics, sexual and reproductive health services and children's centres. Weight management before, during and after pregnancy (PH27) © NICE 2018. All rights reserved. Subject to Notice of rights ( conditions#notice-of-rights). Page 11 of 59Recommendation 2 Pregnant women Conte Context xt If a pregnant woman is obese this will have a greater influence on her health

2010 National Institute for Health and Clinical Excellence - Clinical Guidelines

167. Risk of Pulmonary and Venous Thromboembolism in Pregnancies After in Vitro Fertilization

concerning pulmonary embolism (PE). The aim is to estimate and compare the risk of both PE and VTE during the the different phases of pregnancy after IVF to that in age and period matched control women. The investigators will use the Swedish National Health Registers to estimate the risk. Condition or disease Pulmonary Embolism Venous Thromboembolism Detailed Description: Background: Occurrence of venous thromboembolism (VTE) during IVF pregnancies has been reported in numerous case reports and in two (...) Posted: February 2, 2012 Last Verified: January 2012 Keywords provided by Professor Peter Henriksson, Danderyd Hospital: Assisted Reproductive Techniques Pregnancy Pulmonary Embolism Venous Thromboembolism Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Embolism Venous Thromboembolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases

2012 Clinical Trials

168. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD Full Text available with Trip Pro

for the management of patients with diabetes and acute or chronic coronary syndromes 33 Recommendations for coronary revascularization in patients with diabetes 35 Recommendations for the type of revascularization in patients with diabetes with stable coronary artery disease, suitable coronary anatomy for both procedures, and low predicted surgical mortality 36 Recommendations for the treatment of heart failure in patients with diabetes 39 Recommendations for the treatment of patients with type 2 diabetes (...) plasma glucose ABI Ankle–brachial index ABPM Ambulatory blood pressure monitoring ACCORD Action to Control Cardiovascular Risk in Diabetes ACE Acarbose Cardiovascular Evaluation ACEI Angiotensin-converting enzyme inhibitor ACS Acute coronary syndrome ADA American Diabetes Association ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation ADDITION Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care ADOPT

2019 European Society of Cardiology

169. Disorders of the Hepatic and Mesenteric Circulation Full Text available with Trip Pro

Abstract Disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries have important clinical consequences and may lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma. Although literature in the field of vascular liver disorders is scant, these disorders are common in clinical practice, and general practitioners, gastroenterologists, and hepatologists may benefit from expert guidance (...) and recommendations for management of these conditions. These guidelines represent the official practice recommendations of the American College of Gastroenterology. Key concept statements based on author expert opinion and review of literature and specific recommendations based on PICO/GRADE analysis have been developed to aid in the management of vascular liver disorders. These recommendations and guidelines should be tailored to individual patients and circumstances in routine clinical practice. INTRODUCTION

2020 American College of Gastroenterology

170. Crizanlizumab, Voxelotor, and L-Glutamine for Sickle Cell Disease: Effectiveness and Value

that some individuals experience post-traumatic stress disorder following severe episodes of illness. Among non-specialist providers, we heard there is often the misperception that SCD is a pain condition. This over-simplification can lead to inappropriate care of the disease’s many complications. In the ER, treatment with fluids, oxygen, and other medicines may be lacking and patients may be not be appropriately triaged. One caregiver, “Too often Sickle Cell Patients are marginalized, treated (...) - Crizanlizumab, Voxelotor, and L-Glutamine for SCD Return to Table of Contents List of Acronyms Used in this Report AE Adverse event ACS Acute chest syndrome AKI Acute kidney injury BPI Brief Pain Inventory CI Confidence interval CKD Chronic kidney disease CMS Centers for Medicare and Medicaid Services ED Emergency department FDA Food and Drug Administration GDP Gross domestic product HB Hemoglobin HR Hazard ratio IQR Interquartile range ITT Intent-to-Treat LS least squares LY Life year MCC Major

2020 California Technology Assessment Forum

171. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders

disorders in pregnancy. Haemophilia 2012; 18: 25-33. White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, Courter S. Clinical evaluation of recombinant factor IX. Semin Hematol. 1998; 35 (Suppl. 2):33-38. Shapiro AD, Ragni M, Lusher JM, Culbert S, Koerper MA, Bergman, GE, Hannan MM. Safety and efficacy of monoclonal antibody-purified factor IX in patients previously unexposed to PCC or other blood products. Thromb Haemostas 1996; 75:30-35. Scharrer I. The treatment of von Willebrand disease (...) Licensed for the Treatment of Hemophilia and Other Bleeding Disorders Date: April 23, 2018 ID: 253 Revisions: 250; 249; 246; 240; 237; 235; 225; 218; 215; 210; 205; 202; 195; 190; 187; 182; 177 Attachment Size 173.75 KB 254.93 KB Recommendations for Physicians Treating Patients with Hemophilia A and B, von Willebrand Disease, and other Congenital Bleeding Disorders: A. Treatment of Hemophilia A 1. Recombinant Factor VIII Concentrates Recombinant (r) FVIII is often produced by two well-established

2020 National Hemophilia Foundation

172. American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases

are not elevated (157,158). We conditionally recommend treatment with CYC for life-threatening conditions in the second or third trimester (86). When potentially teratogenic medications are dis- continued prior to pregnancy, we strongly recommend a period of observation without medication or transition to pregnancy-compatible medications to ensure disease stability (as discussed above). In women with inadvertent exposure to teratogenic medications we strongly suggest immediate referral to a maternal-fetal (...) , but discontinuing once she is found to be pregnant. If disease cannot be controlled with medications considered compatible with pregnancy, the physician and patient should dis- cuss and weigh the possible risks from these medications versus the risks of uncontrolled disease during pregnancy. We conditionally recommend continuing treatment with rituximab while a woman is trying to conceive, and we conditionally recommend continuing rituximab during pregnancy if severe life- or organ-threatening maternal dis

2020 American College of Rheumatology

173. AIM Clinical Appropriateness Guidelines for Pharmacogenetic Testing and Genetic Testing for Thrombotic Disorders

Multi-gene pharmacogenomic genotyping assays in which each included target does not meet the above criteria are not medically necessary. Thrombophilia Testing Testing for common variants in Factor V Leiden (F5) and prothrombin (F2) is medically necessary for any of the following indications: ? Pregnant woman who has a personal history of a venous thromboembolism (VTE) ? In an individual with an unprovoked VTE (e.g. not associated with fracture, surgery, prolonged immobilization, cancer) when test (...) , HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder Background Pharmacogenomic Testing Pharmacogenomic testing is utilized as a tool in the field of precision medicine. Precision medicine can guide optimal health care decisions by identifying individual variability to direct approaches for prevention, diagnosis, and treatment of disease (Collins and Varums 2015). As this approach to clinical

2020 AIM Specialty Health

174. Antiphospholipid syndrome

Antiphospholipid syndrome Antiphospholipid syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Antiphospholipid syndrome Last reviewed: February 2019 Last updated: March 2018 Summary Persistently elevated antiphospholipid antibodies associated with thromboses and pregnancy-related morbidity are key diagnostic criteria. Predisposes to arterial and microvascular thrombosis, as well as venous thromboembolism (...) , and can affect any vessel in the body. Main treatment goals are management of acute thrombosis and prevention of thrombosis recurrence and pregnancy morbidity. Consideration should also be given to the presence of co-existent autoimmune disease in patients with antiphospholipid syndrome. Catastrophic disease, which presents as multiorgan failure, occurs in <1% of patients. High index of suspicion for antiphospholipid syndrome in any young patient (<50 years) presenting with arterial thrombosis in any

2018 BMJ Best Practice

175. Thromboembolism in pregnancy. Full Text available with Trip Pro

Thromboembolism in pregnancy. 476455 1979 11 29 2013 11 21 0007-1447 2 6185 1979 Aug 04 British medical journal Br Med J Thromboembolism in pregnancy. 333 Orme M L ML Serlin M J MJ Breckenridge A A eng Letter England Br Med J 0372673 0007-1447 5Q7ZVV76EI Warfarin AIM IM Breast Feeding Female Humans Pregnancy Puerperal Disorders drug therapy Thromboembolism drug therapy Warfarin therapeutic use 1979 8 4 1979 8 4 0 1 1979 8 4 0 0 ppublish 476455 PMC1595688

1979 British medical journal

176. Pulmonary Embolism in Pregnancy

Pulmonary Embolism in Pregnancy Pulmonary Embolism in Pregnancy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pulmonary Embolism (...) in Pregnancy Pulmonary Embolism in Pregnancy Aka: Pulmonary Embolism in Pregnancy II. Epidemiology See Two thirds of thromboembolic events in pregnancy are DVT (diagnosable by ) Overall risk of Pulmonary Embolism in Pregnancy: 3 in 10,000 Risk of increases with advancing pregnancy and especially postpartum First trimester : 1 in 50,000 Third trimester : 1 in 10,000 Two thirds of pregnancy-related occur postpartum (esp after ) III. Symptoms and signs See may be present Unilateral leg signs of may be present

2018 FP Notebook

177. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. Full Text available with Trip Pro

or >97th centile. Conditional Poisson regression analysis was used to generate rate ratios and 95% confidence intervals, adjusting for additionally prescribed non-antipsychotic psychotropic medications.Compared with non-users, women prescribed an antipsychotic medication in pregnancy did not seem to be at higher risk of gestational diabetes (rate ratio 1.10 (95% CI 0.77 to 1.57)), hypertensive disorders of pregnancy (1.12 (0.70 to 1.78)), or venous thromboembolism (0.95 (0.40 to 2.27)). The preterm (...) coverage, those with ≥ 2 consecutive prescriptions for an antipsychotic medication during pregnancy, at least one of which was filled in the first or second trimester, were selected. Of these antipsychotic drug users, 1021 were matched 1:1 with 1021 non-users by means of a HDPS algorithm.The main maternal medical outcomes were gestational diabetes, hypertensive disorders of pregnancy, and venous thromboembolism. The main perinatal outcomes were preterm birth (<37 weeks), and a birth weight <3rd

2015 BMJ

178. Pulmonary hypertensive vascular changes in lungs of patients with sudden unexpected death. Emphasis on congenital heart disease, Eisenmenger syndrome, postoperative deaths and death during pregnancy and postpartum. Full Text available with Trip Pro

Pulmonary hypertensive vascular changes in lungs of patients with sudden unexpected death. Emphasis on congenital heart disease, Eisenmenger syndrome, postoperative deaths and death during pregnancy and postpartum. Pulmonary hypertension (PH) in asymptomatic patients is a rare cause of sudden death. This study aims to determine the incidence of this entity and raise awareness among pathologists.We retrospectively investigated 44 cases of sudden unexpected death in relation to PH in patients (...) heart disease. The cause of PH was recognised as congenital heart disease in 27 patients (61.36%), 14 of whom had simple congenital heart disease, such as atrial or ventricular septal defect,and 13 had complex congenital heart disease with associated atrial septal defect or ventricular septal defect. The remaining 17 patients (29.55%) suffered from primary PH due to plexiform arteriopathy, veno-occlusive disease and thromboembolic disease. Extensive sampling of the lungs is required to detect

2014 Journal of Clinical Pathology

179. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting Full Text available with Trip Pro

, including TTE at 4- to 8-week intervals during pregnancy and during the first 6 months postpartum (⨁◯◯◯). R 3.13. We suggest that CMR imaging (without gadolinium) should be performed during pregnancy when there is suspicion of disease of the distal ascending aorta, aortic arch or descending aorta (⨁◯◯◯). R 3.14. We recommend that blood pressure control is strict (135/85 mmHg) in all pregnant women with TS (⨁◯◯◯). R 3.15. We suggest that during pregnancy, prophylactic surgery is reasonable in case (...) suggest that ART or spontaneous conception should be avoided in case of an ascending aortic size index (ASI) of >2.5 cm/m 2 or an ascending ASI 2.0–2.5 cm/m 2 with associated risk factors for aortic dissection (AoD), which include bicuspid aortic valve, elongation of the transverse aorta, coarctation of the aorta and hypertension (⨁◯◯◯). R 3.10. We suggest that women with a history of AoD should be advised against pregnancy. If already pregnant these women should be followed very closely

2016 European Society of Human Reproduction and Embryology

180. International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS)

(irregular menstrual cycles, hirsutism, infertility and pregnancy complications) [9] and metabolic features (insulin resistance (IR), metabolic syndrome, prediabetes, type 2 diabetes (DM2) and cardiovascular risk factors) [10, 11]. Diagnosis and treatment of PCOS remain controversial with challenges defining individual components within the diagnostic criteria, significant clinical heterogeneity generating a range of phenotypes with or without obesity, ethnic differences and variation in clinical (...) International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS) International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018Publication approval The guideline recommendations on pages 16 to 34 of this document were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 2 July 2018 under section 14A of the National Health and Medical Research Council Act 1992

2018 European Society of Human Reproduction and Embryology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>